Arexvy (Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted))
- Region
- 🇪🇺 EU
- Active substance
- Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Authorised
- Therapeutic area
- Respiratory Syncytial Virus Infections
- CHMP opinion
- Wed 26 Apr 2023
- EU approval
- Tue 06 Jun 2023
- Application
- EMEA/H/C/006054
- ATC
- J07BX05
- Official record
- www.ema.europa.eu
Indication
Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Arexvy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.